Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

January 16, 2025

a250116_00.png

Next: SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat